Europe recommends approval for first stem-cell therapy

LONDON (Reuters) – European regulators have recommended approval of the first medicine containing stem cells to treat a rare condition caused by burns to the eye. The European Medicines Agency said on Friday that Holoclar, from privately held Italian company Chiesi, had been given a green light for moderate to severe limbal stem cell deficiency due to physical or chemical burns. Left untreated, the condition can result in blindness. Holoclar is a living tissue product made from a biopsy taken from a small undamaged area of the patient’s cornea and grown in the laboratory using cell culture. …
Go to Source